SCHEMBL2454681

SCHEMBL2454681

O=c1c(Cc2ccc(F)c(Cl)c2)c(C2CCC2)[nH]c2ncnn12

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 10/20 0.44
MAPK1 P28482 1/20 0.36
DAO P14920 1/20 0.35
PDE1B Q01064 1/20 0.35
PARP1 P09874 2/20 0.35
CCR2 P41597 1/20 0.34
CCR5 P51681 1/20 0.34
NR3C1 P04150 1/20 0.34
PLAT P00750 1/20 0.33
PGR P06401 1/20 0.33
PREP P48147 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2454917 0.92 PDE2A (0.44) PDE2APDE1BCCR2CCR5NR3C1
SCHEMBL2457418 0.91 CCR2 (0.42) PDE2APDE1BCCR2CCR5NR3C1
SCHEMBL2456944 0.91 PDE2A (0.41) PDE2APDE1BNR3C1
SCHEMBL2457053 0.87 PDE2A (0.45) PDE2ANR3C1PREP
SCHEMBL2460219 0.86 CCR2 (0.46) PDE2APDE1BCCR2CCR5NR3C1
SCHEMBL2456756 0.86 PDE2A (0.46) PDE2ANR3C1
SCHEMBL2455230 0.85 PDE2A (0.38) PDE2ADAONR3C1
SCHEMBL2456663 0.84 CCR2 (0.48) PDE2APDE1BCCR2CCR5NR3C1
SCHEMBL2455160 0.84 CCR2 (0.43) PDE2ADAOPDE1BCCR2NR3C1
SCHEMBL2465875 0.84 NR3C1 (0.33) PDE2ANR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011114148-A1 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2011-09-22 WO claimed
WO-2011114148-A1 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2011-09-22 WO disclosed
WO-2011114148-A1 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2011-09-22 WO disclosed